Plasminogen high-affinity lysine-binding site (PLG-LBS) (PLG-LBS)

Plasminogen is a circulating zymogen that, when activated to the serine protease plasmin, plays a central role in fibrinolysis by degrading fibrin clots (Source: UniProt P00747). The high-affinity lysine-binding site (LBS) is a specialized pocket located within the first of five kringle domains (K1) of the plasminogen molecule (Source: PubMed PMID: 11473105). This site is crucial for the recruitment of plasminogen to fibrin surfaces and cell receptors, where it is subsequently activated by tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA) (Source: PubChem CID 5526). By binding to C-terminal lysine residues on partially degraded fibrin, the LBS facilitates the localized generation of plasmin, ensuring efficient clot dissolution. In clinical practice, this site is the primary target for antifibrinolytic drugs such as tranexamic acid and aminocaproic acid (Source: StatPearls, Antifibrinolytics). These lysine analogs competitively occupy the LBS, preventing plasminogen from associating with fibrin and thereby inhibiting the breakdown of blood clots. This therapeutic intervention is vital in managing heavy menstrual bleeding, surgical hemorrhage, and trauma-induced coagulopathy. Beyond its role in hemostasis, the LBS-mediated interactions are involved in extracellular matrix remodeling and cell migration, making it a significant focus in vascular biology and oncology.

Other names

Kringle 1 lysine-binding siteLBS1Plasminogen K1 LBSHigh-affinity LBS

Competitive inhibition of plasminogen and plasmin binding to fibrin lysine residues, thereby preventing fibrinolysis.